Journal Article

Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis

Wanner, Christoph, Ritz, Eberhard, Mann, Johannes F.E, Krane, Vera, März, Winfried, Olschewski, Manfred, Ruf, Günther

2005

Overview

Statins reduce cardiovascular events in persons with type 2 diabetes mellitus. This study randomly assigned patients with type 2 diabetes receiving hemodialysis to receive 20 mg of atorvastatin per day or matching placebo. Atorvastatin reduced all cardiac events combined but not all cerebrovascular events combined or total mortality. In patients with type 2 diabetes receiving hemodialysis and 20 mg of atorvastatin per day, atorvastatin reduced all cardiac events combined but not all cerebrovascular events combined or total mortality. Primary and secondary prevention trials, including those involving persons with diabetes mellitus, have documented substantial cardiovascular benefit from the administration of statins. 1 , 2 The recent Collaborative Atorvastatin Diabetes Study (CARDS) reported a decrease in deaths from cardiovascular causes among persons with type 2 diabetes mellitus in the absence of marked renal insufficiency. 3 There are no prospective data on the effects of statins in patients with end-stage renal disease with type 2 diabetes mellitus who are receiving hemodialysis, although type 2 diabetes is the most common diagnosis among patients at excessive risk of cardiovascular events 4 whose condition requires hemodialysis in both . . .

• Publisher: Massachusetts Medical Society
• Subject: Aged / Atorvastatin Calcium / Biological and medical sciences / Cardiovascular disease / Cerebrovascular Disorders - epidemiology / Cerebrovascular Disorders - prevention & control / Cholesterol, LDL - blood / Diabetes / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - drug therapy / Diabetes Mellitus, Type 2 - mortality / Diabetes Mellitus, Type 2 - therapy / Diabetes. Impaired glucose tolerance / Double-Blind Method / Endocrine pancreas. Apud cells (diseases) / Endocrinopathies / Etiopathogenesis. Screening. Investigations. Target tissue resistance / Female / General aspects / Heart Diseases - epidemiology / Heart Diseases - mortality / Heart Diseases - prevention & control / Hemodialysis / Heptanoic Acids - adverse effects / Heptanoic Acids - therapeutic use / Humans / Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects / Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use / Incidence / Male / Medical diagnosis / Medical sciences / Middle Aged / Myocardial Infarction - epidemiology / Myocardial Infarction - prevention & control / Patients / Prospective Studies / Pyrroles - adverse effects / Pyrroles - therapeutic use / Renal Dialysis / Statins / Stroke - chemically induced / Stroke - mortality / Stroke - prevention & control